CV Sciences (CVSI)
(Delayed Data from OTC)
$0.04 USD
0.00 (0.22%)
Updated Sep 20, 2024 02:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
CV Sciences, Inc. [CVSI]
Reports for Purchase
Showing records 1 - 20 ( 67 total )
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Weekly ReHash: 2Q23 Week III U.S. Cannabis Earnings
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Cannabis Industry Update: Week III Earnings Preview
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q Soft, Right Sizing to Reach CF+ in Consolidating CBD Market, PT $0.05
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Cannabis Industry Update: 2Q22 Week II Earnings Preview
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Seasonally Weak with Continuing Margin Pressure, Neutral
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Cannabis Earnings 1Q22: Week III Preview
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Soft, Product Innovation Offset by Industry Weakness, PT to $0.20
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Weekly ReHash: California To See Lots of Changes in 2022, Positive Developments
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company Update, Expanding Distribution Through GNC, New SKU Launches
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Rehash: Historical Analysis of Valuations, Declining Cost of Capital
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Soft in Challenging Space, New Products Set Up 2022, Remain Neutral
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: CV Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Cannabis State of the Industry: Industry Challenges Remain, Growth Story Intact
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S